Visterra joins Otsuka Pharmaceutical

Otsuka Pharmaceutical to acquire Visterra in a merger agreement

Register for free to listen to this article
Listen with Speechify
Tokyo and Waltham, Mass.—Otsuka Pharmaceutical Co., Ltd. and Visterra, Inc. have announced that they have entered into a definitive merger agreement, pursuant to which Otsuka will acquire Visterra for approximately US $430 million in an all-cash transaction. The Otsuka and Visterra boards of directors have both approved the transaction. Subject to customary closing conditions, including expiration or termination of the waiting period under U.S. antitrust laws, the transaction is expected to close in the third quarter of 2018.
Tatsuo Higuchi, president and representative director of Otsuka Pharmaceutical commented, “I am highly gratified that Visterra’s exceptional antibody platform technology, promising pipeline and talented researchers will join up with Otsuka. By collaborating and reinforcing each other’s culture, human ingenuity and technology, we hope to help fulfill Visterra’s promise as a powerful new drug creation engine and expand Otsuka’s research horizons.”
Visterra’s proprietary Hierotope platform, comprised of novel computational and experimental technologies, enables the design and engineering of precision antibody-based therapies that specifically bind to, and modulate, key disease targets that are not adequately addressed by current technologies in antibody therapeutics. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates.  Visterra’s pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases.
Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, and kidney, cardiovascular and infectious diseases. The company is placing emphasis on proprietary drug discovery and development platforms, including antibody development platforms, as a means to increase the efficiency of drug discovery across its programs and as an addition to conventional R&D processes.
“This transaction affirms the power of Visterra’s novel technology platform, the promise of our product candidates, and the value our employees and shareholders have created. Our two companies share a common culture of creativity and innovation, and commitment to patients with kidney diseases, cancer and other hard-to-treat diseases. Joining forces with Otsuka will provide Visterra the resources, support and commitment to accelerate development of our pipeline and fully realize the potential of our technology platform,” said Brian J. G. Pereira, MD, CEO of Visterra.
Following completion of the acquisition, Visterra will be a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan. Visterra will continue to operate its business and develop its pipeline as a member of the Otsuka family of companies, retaining its talent and its location in Waltham, Massachusetts.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue